Immuno-oncology drugs and agents with novel MoAs to further influence treatment paradigms in cancer indications in 2020, says GlobalData

Immuno-oncology drugs and agents with novel MoAs to further influence treatment paradigms in cancer indications in 2020, says GlobalData As 2020 commences for the pharmaceutical industry, Fern Barkalow, PhD, Senior Director of Oncology and Hematology, as well as members of her analyst team at leading data and analytics company GlobalData comment on some of the … Continue reading Immuno-oncology drugs and agents with novel MoAs to further influence treatment paradigms in cancer indications in 2020, says GlobalData

Ontario continues to improve access to treatment for children and adolescents living with ADHD who are prescribed INTUNIV XR®*

Ontario continues to improve access to treatment for children and adolescents living with ADHD who are prescribed INTUNIV XR®* Ontario publicly reimburses INTUNIV XR® (guanfacine hydrochloride extended-release tablets) for both adjunctive and monotherapy treatment of children and adolescents with ADHD TORONTO, Jan. 24, 2020 /CNW/ – Takeda Canada Inc. is pleased to announce that effective January … Continue reading Ontario continues to improve access to treatment for children and adolescents living with ADHD who are prescribed INTUNIV XR®*

Novacap to Sell Majority Stake in Intelerad Medical Systems

Novacap to Sell Majority Stake in Intelerad Medical Systems Novacap, founders, and management shareholders will reinvest alongside new partner MONTREAL, Jan. 23, 2020 /CNW Telbec/ – Novacap, the Canadian-based private equity firm, announced today that it has entered into a definitive agreement for the sale of a majority stake in Intelerad Medical Systems (“Intelerad”), a global … Continue reading Novacap to Sell Majority Stake in Intelerad Medical Systems

Health Canada Approves KEYTRUDA® (pembrolizumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC)

Health Canada Approves KEYTRUDA® (pembrolizumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC) Approval Based on Results of KEYNOTE-426, Where KEYTRUDA® in Combination with Axitinib Reduced the Risk of Death by Nearly Half Compared to Sunitinib Renal cell carcinoma (RCC) is the most common form of kidney cancer, representing 80 per cent of all … Continue reading Health Canada Approves KEYTRUDA® (pembrolizumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC)

Federal Government Misled Public on E-Cigarette Health Risk: CEI Report

Federal Government Misled Public on E-Cigarette Health Risk: CEI Report WASHINGTON, January 22 – A new report from the Competitive Enterprise Institute calls into question government handling of e-cigarette risk to public health, especially last week after the U.S. Centers for Disease Control and Prevention (CDC) tacitly conceded that the spate of lung injuries widely reported in … Continue reading Federal Government Misled Public on E-Cigarette Health Risk: CEI Report